Brazil allows sale of cannabis-based MS drug

Brazil’s health care regulator, Anvisa, handed out the nation’s first license for the sale of a cannabis-based drug – one designed for the treatment of multiple sclerosis.

According to Reuters, U.K.-based GW Pharmaceuticals PLC developed the marijuana-based oral spray, which is known internationally as Sativex. It will be marketed in Brazil as Mevatyl.

Anvisa announced Monday it had issued a license to São Paulo-based Beaufour Ipsen Farmacêutica to sell and distribute the drug.

Sativex is already sold in 28 other countries, according to Anvisa.

For several years, Brazilian patients have waged a legal battle to get around prohibitions targeting cannabis-based medicines. But in the past couple of years, according to Reuters, Anvisa has loosened some restrictions and allowed patients with medical recommendations to import marijuana-based medicines.

Brazil decriminalized growing and possessing small amounts of cannabis and other drugs more than a decade ago, Reuters reported. But buying and selling cannabis is still not allowed.

One comment on “Brazil allows sale of cannabis-based MS drug
  1. Angelo on

    “Brazil decriminalized growing and possessing small amounts of cannabis and other drugs more than a decade ago, Reuters reported. But buying and selling cannabis is still not allowed.”

    That’s only a de jure status, de facto cannabis growing and possession are still framed as felonies by most police officers – the former as drug trafficking and the later as trafficking or possession of illegal substances, resulting in legal action against the “perpetrator”

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *